Brazil Contraceptive Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Brazil contraceptive devices market size in 2026 is estimated at USD 544.01 million, growing from 2025 value of USD 512.64 million with 2031 projections showing USD 732.11 million, growing at 6.12% CAGR over 2026-2031. This report is Segmented by Type (Condoms, Diaphragms and Cervical Caps, Vaginal Sponges, Vaginal Rings, Intra-Uterine Devices (IUD), Subdermal Implants and More), and Gender (Male, Female), Material (Latex and Non- Latex) and Distribution Channel (Public Health System, Hospital Pharmacies, Retail Pharmacies & Drugstores and More). The Market Forecasts are Provided in Terms of Value (USD).

Brazil Contraceptive Devices Market Trends and Insights

Government initiatives and rising awareness for contraceptive devices

Brazil’s Family Health Strategy now funds 2,360 new teams per year, creating routine touchpoints where nurses and physicians counsel users on a broader mix of methods. The Nova Indústria Brasil policy channels BRL 300 billion into domestic device production, lowering import reliance and shortening lead times. Community-health workers integrate contraception messaging into home visits, enhancing method literacy in underserved districts. A unified procurement model for primary-care units strengthens supply continuity, helping clinics maintain stock of implants, IUDs, and condoms simultaneously. As awareness improves, method switching rises, pushing demand for both short-acting and long-acting products.

Rising burden of sexually transmitted infections (STIs)

A recent multicenter study recorded 24% STI prevalence among pregnant women in major urban hospitals, intensifying public-health campaigns that spotlight condoms for dual protection. Youth-oriented initiatives such as UNFPA’s “Mais Direitos, Menos Zika” reinforce consistent barrier use, driving steady condom replenishment cycles. Clinicians increasingly recommend dual-method strategies, pairing hormonal devices with barrier products, which boosts cross-category sales. Online ordering enables discreet access for high-risk groups, and digital pharmacies bundle condoms with STI self-test kits, raising average transaction value. Manufacturers highlight antiviral lubricant coatings and thinner non-latex options to differentiate premium lines.

Side-effects and discomfort concerns with device/hormonal methods

Surveys in primary-care settings reveal that many women feel constrained by side-effect anxiety, citing cramps, bleeding changes, or weight gain as key discouragers. Insertion of copper IUDs remains uneven because some clinics still impose unnecessary eligibility criteria. Device withdrawal rates highlight counseling gaps, where expectations for initial adjustment go unaddressed. Pharmaceutical firms respond with patient-friendly leaflets and 24-hour chatbots that clarify typical adaptation timelines. Training initiatives for nurses now incorporate updated pain-management protocols and shared decision-making techniques to rebuild confidence in LARC safety.

Other drivers and restraints analyzed in the detailed report include:

• Growing rate of unplanned adolescent pregnancies
• ANVISA 2024-25 e-labelling and streamlined import rules
• Cultural resistance and misinformation around LARCs

Segment Analysis

Condoms contributed 43.02% to the Brazil contraceptive devices market in 2025, supported by broad retail coverage and dual-protection messaging. Subdermal implants, while accounting for a smaller base, are on track for a 7.12% CAGR through 2031 as public clinics scale LARC programs. The Brazil contraceptive devices market size for implants is projected to grow steadily as domestic factories, financed under Nova Indústria Brasil, ramp up output. Condom vendors emphasize non-latex SKUs and antiviral lubricants to command premium shelf placement, whereas implant producers invest in provider training to boost insertion competencies across family-health teams.

Supply-chain volatility for copper complicates IUD production, yet localized assembly mitigates part of the pricing pressure. Vaginal rings gain niche appeal among health-conscious urban women seeking routine-free hormonal delivery. Diaphragms, cervical caps, and sponges remain niche because they require fitting or carry lower efficacy perceptions. Emerging “other devices,” including stimuli-responsive hydrogels, signal future avenues for reversible male and female contraception, though commercial impact lies beyond the current forecast horizon.

Female-focused products held 68.25% share in 2025, but male devices are positioned for an 7.89% CAGR as societal attitudes evolve toward shared responsibility. A push for dual-method use means condom demand coexists with hormonal and LARC adoption, rather than replacing it. Promotional campaigns now feature couple-based narratives, encouraging joint decision-making at clinic visits. Retailers report that multipacks sized for month-long use appeal to budget-sensitive male buyers; meanwhile, telehealth platforms experiment with mail-order vasectomy consultations, expanding the Brazil contraceptive devices industry reach.

Female device growth stems from expanding implant and IUD programs financed by state and municipal authorities. Manufacturers embed QR codes on packaging that link users to removal service locators, reducing anxiety around reversibility. As more men participate in contraceptive conversations, brands offering discreet male options, such as soon-to-launch reversible gels, stand to diversify revenue streams in the Brazil contraceptive devices market.

Complete Report Scope:

• By Type
  • Condoms
  • Diaphragms and Cervical Caps
  • Vaginal Sponges
  • Vaginal Rings
  • Intra-Uterine Devices (IUD)
  • Subdermal Implants
  • Spermicidal Devices
  • Other Devices
• By Gender
  • Male
  • Female
• By Material
  • Latex
  • Non-latex
• By Distribution Channel
  • Public Health System
  • Hospital Pharmacies
  • Retail Pharmacies & Drugstores
  • E-commerce & Direct Sales
  • Family-planning Clinics & NGO Programs

List of Companies Covered in this Report:

• LifeStyles Healthcare
• Ansell
• Bayer
• Church & Dwight
• Reckitt Benckiser Group
• The Cooper Companies
• Veru
• Merck
• Organon
• Hypera Pharma S.A.
• DKT International
• Skyn
• Linepharma International
• Mithra Pharmacueticals
• Cupid Ltd
• Okamoto Industries Inc.
• Gedeon Richter Plc

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support